Other Health

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Retrieved on: 
Wednesday, May 1, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Mesothelioma, Imerys, Safety, State, JNJ, Bankruptcy, Johnson & Johnson, MDL, Science, Worldwide, Cyprus Mines Corporation, Talc, LLT, Ovarian cancer, Insurance

“The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.

Key Points: 
  • “The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.
  • The remaining pending personal injury lawsuits relate to mesothelioma and will be addressed outside of the Plan.
  • The State consumer protection claims will also be addressed outside the Plan; the Company already has agreements in principle to do so.
  • In light of those risks, counsel representing the overwhelming majority of current ovarian claimants assisted in the development and support the Plan.

CONMED Corporation to Present at the BofA Securities Healthcare Conference

Retrieved on: 
Wednesday, May 1, 2024
Medical Supplies, Medical Devices, Health, Surgery, Health Technology, Other Health, Chairperson, Conference

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m.

Key Points: 
  • CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m.
  • ET) on Tuesday, May 14, 2024 in Las Vegas, NV.
  • A live audio webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com and will be available for replay following the event.

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

Retrieved on: 
Wednesday, May 1, 2024
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Education, Health equity, Lupus nephritis, Lupus Research Alliance, Lupus, Partnership, Rheumatology, Autoimmune disease, Patient, Diagnosis, SLE, Pharmaceutical industry

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.

Key Points: 
  • In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
  • Through awareness, education, advocacy, and partnerships with the LN community, the Aurinia team is working to help eliminate barriers to access, promote equity, and improve health outcomes for those impacted by LN.
  • “Since its inception, Aurinia has stood tall as a dedicated leader in overtaking one of the toughest challenges in autoimmune disease – lupus nephritis,” said Peter Greenleaf, Chief Executive Officer of Aurinia.
  • As a dedicated partner to the LN community, Aurinia participates in events across the country throughout the year to promote awareness and uplift the people living with LN.

Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration

Retrieved on: 
Wednesday, May 1, 2024
Stem Cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Optical, Other Science, Research, Science, Clinical Trials, AMD, Vance DeGeneres, Cell, Hope, Doctor of Philosophy, Transplant, NSCI, CIRM, Patient, Paratriathlon, RPE, Quality of life, Therapy, Visual impairment

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).

Key Points: 
  • RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).
  • Transplantation of progenitor-stage RPESC-RPE cells obtained after four weeks of differentiation (RPESC-RPE-4W) effectively replace the native RPE cells lost during AMD disease progression.
  • "We are honored to have CIRM recognize the potential of our unique technology utilizing precursor-stage RPE cells.
  • “RPESC-RPE-4W therapy represents a potential breakthrough in the treatment of dry AMD,” said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM.

Zoetis Announces First Quarter 2024 Results

Retrieved on: 
Thursday, May 2, 2024
Health, Other Health, Fitness & Nutrition, General Health, Pharmaceutical, Veterinary, Poultry, OA, Summit, Coccidioides immitis, International, Investment, Weather, Fear, Weight gain, Cattle, Levamisole, Animal, Panic, Horse, Growth, Webcast, Transport, Vaccine, Sarolaner, Metritis, Tick, Cat, MFA, Parasitism, Food, Human, Acquisition, Livestock, Mycoplasma bovis, Inc., Dog, EZ, Sheep, Dermatology, RTU

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024.
  • The company reported revenue of $2.2 billion for the first quarter of 2024, an increase of 10% compared with the first quarter of 2023.
  • On an operational1 basis, revenue for the first quarter of 2024 increased 12% compared with the first quarter of 2023.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review first quarter 2024 results, discuss financial guidance and respond to questions from financial analysts.

TERSA Partners with Nick Littlemore as the Official Music Director of SAVA Sound Pod

Retrieved on: 
Wednesday, May 1, 2024
Hardware, Consumer Electronics, Other Health, Mobile Entertainment, Technology, Audio, Video, Apps, Applications, Celebrity, Mental Health, General Health, Music, Artificial Intelligence, Other Technology, Entertainment, Health, Relaxation, Rejuvenation, Sun, AI, Heart, Emotional intelligence, PNAU, Partnership, Sound, Empire, Consciousness, Multimedia, Meditation, Empire of the Sun

TERSA , the pioneering wellness company dedicated to reinventing holistic human health and high performance, proudly announces the creative partnership with Nick Littlemore as the official Music Director and Investor of TERSA’s SAVA Sound Pod .

Key Points: 
  • TERSA , the pioneering wellness company dedicated to reinventing holistic human health and high performance, proudly announces the creative partnership with Nick Littlemore as the official Music Director and Investor of TERSA’s SAVA Sound Pod .
  • View the full release here: https://www.businesswire.com/news/home/20240501182957/en/
    TERSA Partners with Nick Littlemore as the Official Music Director of SAVA Sound Pod (Graphic: Business Wire)
    Born from CEO and Founder, Ray Kelly's decades-long expertise in injury rehabilitation and holistic wellness, TERSA embodies a holistic approach to well-being that integrates physical, mental, and emotional health.
  • Nick Littlemore's expertise in sound and music is integral to crafting the immersive and transformative experience that SAVA offers.
  • "It has been an honor to collaborate on the creation of SAVA alongside Ray, and curate the unique sound journeys that elevate the SAVA experience," says Nick Littlemore.

U.S. Physical Therapy Announces Acquisitions

Retrieved on: 
Wednesday, May 1, 2024
Other Health, Professional Services, Other Construction & Property, Hospitals, Construction & Property, Other Manufacturing, Other Transport, Human Resources, Transport, Manufacturing, Health, Physical Therapy, Partnership, Acquisition, IIP

Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), announced the acquisition of an IIP services business by one of its primary IIP companies, Briotix Health Limited Partnership (“Briotix”).

Key Points: 
  • Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), announced the acquisition of an IIP services business by one of its primary IIP companies, Briotix Health Limited Partnership (“Briotix”).
  • Briotix purchased 100% of the IIP services business for a total purchase price of approximately $24.0 million.
  • In a separate transaction, USPH also acquired a two-clinic physical therapy practice with approximately $1.0 million in annual revenue, which is being tucked into a larger recently acquired practice.
  • Chris Reading, Chief Executive Officer, said, “We are extremely pleased to announce our industrial injury prevention acquisition today.

John B. Sanfilippo & Son, Inc. Reports Fiscal 2024 Third Quarter Results

Retrieved on: 
Wednesday, May 1, 2024
Other Health, Men, General Health, Family, Supermarket, Consumer, Food, Beverage, Fitness & Nutrition, Retail, Other Consumer, Women, Health, PIN, Hand, Webcast, Environment, Pressure, Acquisition, EPS, Advertising, Telephone, TreeHouse Foods

John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced financial results for its fiscal 2024 third quarter ended March 28, 2024.

Key Points: 
  • John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced financial results for its fiscal 2024 third quarter ended March 28, 2024.
  • “Sales volume for the third quarter, excluding the impact of the Lakeville Acquisition, decreased 1.4% mainly due to decreased sales volume in our contract packaging sales channel.
  • * Results include the impact of the acquisition of the TreeHouse Foods snack bar business (the “Lakeville Acquisition”) which was completed on September 29, 2023, the first day of our second fiscal quarter.
  • Net sales for the third quarter of fiscal 2024 increased $33.3 million, or 14.0%, to $271.9 million and included approximately $46.9 million of net sales from the Lakeville Acquisition.

Worldwide Clinical Trials Recognized with Coveted 2024 CRO Leadership Awards Based on Customer Feedback for 11th Consecutive Year

Retrieved on: 
Wednesday, May 1, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Operational excellence, Communication, Partnership, ChromeOS, Trust, ISR, Fine chemical

Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines.

Key Points: 
  • Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines.
  • This marks the 11th consecutive year that Worldwide is rated as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals, with this year’s distinction augmented by additional honors as a Champion in several pivotal categories.
  • Earlier this year, Worldwide released the results of its 2024 industry survey , a report that examines the changing perceptions about large and midsize CROs within the pharmaceutical and biotech sectors.
  • The CRO Leadership Awards serve as a beacon of trust and quality within the pharmaceutical industry, helping stakeholders identify CRO partners that are not just capable, but exemplary.

Susan G. Komen® Urges Personalized Approach in Response to Breast Cancer Screening Recommendations

Retrieved on: 
Tuesday, April 30, 2024
Women, Advocacy Group Opinion, Public Policy, Government, Other Health, Radiology, Health, Consumer, General Health, Oncology, Education, Risk, Woman, CDC, USPSTF, Partnership, Confusion, Science, Patient, Medicine, Cancer, Breast cancer, Birth control

In a rapidly evolving landscape shaped by advances in science and technology, Komen emphasizes the pressing necessity of personalized screening and treatment plans.

Key Points: 
  • In a rapidly evolving landscape shaped by advances in science and technology, Komen emphasizes the pressing necessity of personalized screening and treatment plans.
  • Each individual's unique risk factors, including family history, genetic predisposition, and lifestyle factors, must be carefully considered to optimize screening effectiveness and improve outcomes.
  • These recommendations may cause additional confusion to patients, particularly for individuals with dense breasts or a family history of breast cancer and may create barriers to screening services.
  • As steadfast advocates for breast health, Komen remains committed to advancing screening practices, promoting evidence-based guidelines, ensuring affordable access, and improving outcomes in the fight against breast cancer.